[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endovascular-thrombectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endovascular-thrombectomy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,47,68,91,118,141,167,192,215,243,267],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100637603","phase-2-minocycline-after-successful-endovascular-thrombectomy-recanalization-in-acute-anterior-circulation-large-vessel-occlusion-attraction-minoa-100637603",false,"NCT07594314","Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)","Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Anterior Circulation Large Vessel Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Pre-stroke mRS score of 0-1;\n3. Time from symptom onset to randomization ≤24 hours, including wake-up stroke or unwitnessed stroke. Symptom onset is defined as the last known well time;\n4. Baseline NIHSS score of 6-25;\n5. ASPECTS ≥6 on non-contrast CT or DWI;\n6. Clinical symptoms attributable to acute occlusion at one of the following sites, confirmed by CTA, MRA, or DSA: intracranial internal carotid artery, M1 segment of the middle cerebral artery, or M2 trunk of the MCA;\n7. Successful recanalization defined as mTICI 2b-3 after mechanical thrombectomy, with no evidence of secondary embolization in non-target vessels; or spontaneous improvement to mTICI 2b-3 on diagnostic angiography prior to thrombectomy with no planned intervention;\n8. Ability of the patient or legally authorized representative to provide written informed consent.\n\nExclusion Criteria:\n\n1. Acute intracranial hemorrhage on CT or MRI;\n2. Bilateral acute stroke or multiple intracranial large vessel occlusions;\n3. Isolated extracranial internal carotid artery occlusion;\n4. History of pseudomembranous colitis or antibiotic-associated colitis;\n5. Known allergy to tetracycline antibiotics, any component of the investigational drug, radiocontrast agents, or nitinol materials;\n6. Known resistance to tetracycline antibiotics;\n7. Use of tetracycline antibiotics within 7 days prior to randomization;\n8. History of intracranial hemorrhage within the past 3 months, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma;\n9. Intracranial tumors, vascular malformations, or other space-occupying intracranial lesions;\n10. History of intracranial or spinal surgery within the past 3 months;\n11. History of major surgery or significant trauma within the past 1 month;\n12. Receipt of any of the following treatments within the past 3 months: systemic retinoic acid or androgen\u002Fantiandrogen therapy (e.g., anabolic steroids, spironolactone);\n13. Platelet count \\\u003C100 × 10⁹\u002FL;\n14. Severe hepatic insufficiency, chronic hemodialysis, or severe renal insufficiency (defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>265.2 μmol\u002FL \\[3.0 mg\u002FdL\\]);\n15. Women who are pregnant or lactating, or who have a positive pregnancy test prior to randomization;\n16. Life expectancy \\\u003C6 months (e.g., due to malignancy or severe cardiopulmonary disease);\n17. Participation in another interventional clinical trial that may affect outcome assessment;\n18. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation or poses significant risk (e.g., inability to understand or comply with study procedures or follow-up due to psychiatric, cognitive, or emotional disorders).","ALL","18 Years",{"count":19,"type":20},860,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","Endovascular thrombectomy (EVT) improves outcomes in patients with acute large vessel occlusion (LVO). However, despite successful recanalization rates exceeding 80%, fewer than 50% of patients achieve favorable functional outcomes at 90 days, indicating a high rate of futile recanalization. Potential mechanisms include no-reflow, reperfusion injury, and microcirculatory dysfunction, which are closely associated with post-recanalization neuroinflammation.\n\nMinocycline is a second-generation tetracycline with pleiotropic neuroprotective effects, including inhibition of microglial activation, reduction of inflammatory mediators, suppression of matrix metalloproteinases, attenuation of oxidative stress, and preservation of blood-brain barrier integrity. Prior preclinical and clinical studies suggest that minocycline may improve neurological outcomes in acute ischemic stroke.\n\nThis study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of adjunctive minocycline in patients with acute anterior circulation LVO who achieve successful recanalization after EVT. The trial will assess whether early administration of minocycline improves functional outcomes and reduces futile recanalization.",[27,28,29,30,31],"Acute Ischemic Stroke","Vessel Occlusion","Endovascular Thrombectomy","Anterior Circulation Brain Infarction","Minocycline",[27,29,31,33],"Anterior Circulation Large Vessel Occlusion","RECRUITING","2026-05-22",{"date":37,"type":38},"2026-05-27","ACTUAL",{"date":40,"type":38},"2026-05-21",{"date":42,"type":20},"2028-12",{"name":44,"class":45},"Xiang Luo","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":67,"locationsCount":46},"100637132","phase-2-minocycline-after-successful-endovascular-thrombectomy-recanalization-in-posterior-circulation-arterial-occlusion-attraction-minop-100637132","NCT07594301","Minocycline After Successful Endovascular Thrombectomy Recanalization in Posterior Circulation Arterial Occlusion (ATTRACTION-MINOP)","Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Posterior Circulation Arterial Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Pre-stroke mRS score of 0-1;\n3. Time from symptom onset to randomization ≤24 hours, including wake-up stroke or unwitnessed stroke. Symptom onset is defined as the last known well time;\n4. Baseline NIHSS score ≥6;;\n5. Posterior Circulation ASPECTS ≥6 on non-contrast CT or DWI;\n6. Clinical symptoms attributable to acute occlusion of the intracranial vertebral artery or basilar artery, confirmed by CTA, MRA, or DSA;\n7. Successful recanalization defined as mTICI 2b-3 after mechanical thrombectomy, with no evidence of secondary embolization in non-target vessels; or spontaneous improvement to mTICI 2b-3 on diagnostic angiography prior to thrombectomy with no planned intervention;\n8. Ability of the patient or legally authorized representative to provide written informed consent.\n\nExclusion Criteria:\n\n1. Acute intracranial hemorrhage on CT or MRI;\n2. Occlusion involving both anterior and posterior circulations on CTA, MRA, or DSA (except in patients with a prior history of anterior circulation occlusion);\n3. Complete bilateral thalamic infarction or bilateral brainstem infarction on CT or MRI;\n4. Cerebellar infarction with significant mass effect or compression of the fourth ventricle on CT or MRI;\n5. Vascular anatomy on CTA, MRA, or DSA that is severely tortuous, demonstrates significant anatomical variation, or shows severe stenosis or dissection precluding navigation of thrombectomy devices to the target vessel;\n6. History of pseudomembranous colitis or antibiotic-associated colitis;\n7. Known allergy to tetracycline antibiotics, any component of the investigational drug, radiocontrast agents, or nitinol materials;\n8. Known resistance to tetracycline antibiotics;\n9. Use of tetracycline antibiotics within 7 days prior to randomization;\n10. History of intracranial hemorrhage within the past 3 months, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma;\n11. Intracranial tumors, vascular malformations, or other space-occupying intracranial lesions;\n12. History of intracranial or spinal surgery within the past 3 months;\n13. History of major surgery or significant trauma within the past 1 month;\n14. Receipt of any of the following treatments within the past 3 months: systemic retinoic acid or androgen\u002Fantiandrogen therapy (e.g., anabolic steroids, spironolactone);\n15. Platelet count \\\u003C100 × 10⁹\u002FL;\n16. Severe hepatic insufficiency, chronic hemodialysis, or severe renal insufficiency (defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>265.2 μmol\u002FL \\[3.0 mg\u002FdL\\]);\n17. Women who are pregnant or lactating, or who have a positive pregnancy test prior to randomization;\n18. Life expectancy \\\u003C6 months (e.g., due to malignancy or severe cardiopulmonary disease);\n19. Participation in another interventional clinical trial that may affect outcome assessment;\n20. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation or poses significant risk (e.g., inability to understand or comply with study procedures or follow-up due to psychiatric, cognitive, or emotional disorders).",{"count":55,"type":20},234,[23,24],"Acute ischemic stroke (AIS) is a leading cause of mortality and long-term disability worldwide. Among these, stroke caused by large vessel occlusion (LVO) are associated with particularly poor outcomes. Multiple randomized controlled trials have demonstrated that endovascular thrombectomy (EVT) significantly improves clinical outcomes in patients with acute LVO and is recommended as the standard of care by current guidelines. Posterior circulation strokes account for approximately 20% of all ischemic strokes and are generally associated with worse prognosis than anterior circulation strokes, especially in patients with basilar artery occlusion, who have a markedly increased risk of death or severe disability. Despite EVT treatment, more than three-quarters of these patients remain dead or functionally dependent at 90 days, indicating substantial room for improvement.\n\nSuccessful recanalization and restoration of effective cerebral perfusion are critical for achieving favorable outcomes. However, although recanalization rates exceed 80% with current thrombectomy techniques, fewer than 40 of patients achieve good functional outcomes at 90 days, suggesting a high incidence of futile recanalization. The underlying mechanisms may include no-reflow, reperfusion injury, and microcirculatory dysfunction, all of which are closely associated with post-recanalization neuroinflammation.\n\nMinocycline is a second-generation tetracycline with pleiotropic neuroprotective properties, including inhibition of microglial activation, reduction of inflammatory mediators, suppression of matrix metalloproteinases, attenuation of oxidative stress, and preservation of blood-brain barrier integrity. Preclinical and clinical studies suggest that minocycline may improve neurological outcomes in patients with AIS.\n\nThis study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of adjunctive minocycline in patients with acute posterior circulation arterial occlusion who achieve successful recanalization after EVT. The trial will assess whether early administration of minocycline improves functional outcomes and reduces the incidence of futile recanalization.",[27,29,31,59,60],"Posterior Circulation","Arterial Occlusion",[27,29,31,62],"Posterior Circulation Arterial Occlusion","2026-05-19",{"date":35,"type":38},{"date":63,"type":38},{"date":42,"type":20},{"name":44,"class":45},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":46},"100565221","effects-of-transcranial-magnetic-stimulation-after-endovascular-treatment-for-acute-ischemic-stroke-100565221","NCT06639360","Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old.\n2. Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1\u002FM2 segment of the middle cerebral artery.\n3. A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy.\n4. Pre-stroke mRS score is ≤1.\n5. NIHSS score before thrombectomy is between 6 and 25.\n6. With vascular recanalization of mTICI \\> 2b\u002F3.\n7. Informed consent form signed.\n\nExclusion Criteria:\n\n1. Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc.;\n2. Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and kidneys;\n3. Head CT\u002FMRI indicates midline shift or significant mass effect, or patients planned for surgical intervention;\n4. Head CT\u002FMRI suggests acute cerebral infarction in both sides;\n5. Patients who are pregnant or breastfeeding;\n6. Patients with severe mental disorders or dementia who cannot cooperate with follow-up;\n7. Patients with other severe diseases resulting in an expected survival of less than 90 days;\n8. Patients who are participating in other interventional clinical studies within 30 days before the start of this study or after the onset of this condition;\n9. Patients who cannot cooperate with informed consent.","80 Years",{"count":76,"type":20},60,[78],"NA","This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.",[81,29],"Ischemic Stroke, Acute","2025-11-26",{"date":84,"type":38},"2025-12-04",{"date":86,"type":38},"2025-08-02",{"date":88,"type":20},"2026-12-31",{"name":90,"class":45},"Xijing Hospital",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":46},"100596210","efficacy-and-safety-of-plasma-adsorption-combined-with-evt-for-ais-lvo-100596210","NCT07042490","Efficacy and Safety of Plasma Adsorption Combined With EVT for AIS-LVO","Efficacy and Safety of Plasma Adsorption Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation: A Multicenter, Randomized, Parallel-controlled Clinical Trial","PROMOTE-EVT","Inclusion Criteria:\n\n1. Age 18-80 years, male or female.\n2. Diagnosis of acute ischemic stroke within 12 hours of symptom onset, underwent endovascular thrombectomy (EVT) adhering to current guidelines for large vessel occlusion in the anterior circulation (confirmed by DSA as ICA,MCA-M1,MCA-M2,ACA-A1,ACA-A2 occlusion or tandem lesion) and achieve successful recanalization (mTICI grade 2b\u002F3).\n3. Baseline NIHSS after EVT ≥ 6 and ≤25 points.\n4. Randomization and the first plasma adsorption can be initiated within 12 hours after EVT.\n5. Pre-stroke mRS≤ 2 points.\n6. Patient\u002Flegally family members have signed the Informed consent form.\n\nExclusion Criteria:\n\n1. Imaging after EVT indicated malignant brain edema with midline shift or brain herniation and surgical treatment was planned.\n2. Parenchymal hemorrhage type 1, or type 2 confirmed by CT.\n3. Allergic to any ingredient of the plasma separator, the adsorption device, or the piping.\n4. Contraindications to plasma adsorption, platelet count \\\u003C60×10\\^9\u002FL,white blood cell\\\u003C4×10\\^9\u002FL, uncontrolled hypertension with persistent systolic blood pressure ≥200 mmHg or diastolic blood pressure ≥110 mmHg, uncontrolled hypotension, systolic blood pressure \\\u003C90 mmHg or diastolic blood pressure \\\u003C60 mmHg.\n5. Previous history of malignant tumors, autoimmune diseases or being treated with immunosuppressants, hormones, or tumor necrosis factor inhibitors.\n6. Previous history of organic heart disease and NYHA Class III or IV.\n7. Currently taking anticoagulant(dabigatran, rivaroxiban, warfarin, etc.), previous history of serious hematological system disorders, or abnormal coagulation function (international normalized ratio \\[INR\\], activated partial thromboplastin time \\[APTT\\], prothrombin time \\[PT\\] upper limit of the normal range).\n8. Severe liver and kidney dysfunction or abnormal laboratory test results（serum aspartate aminotransferase or alanine aminotransferase \\>3 times the upper limit of normal, serum creatinine\\>265umol\u002Fl(\\>3mg\u002Fdl)）.\n9. Pregnancy , lactation or life expectancy of less than 3 months or inability to complete the study for other reasons.\n10. Unwilling to be followed up or poor compliance.\n11. Current or past participation in other clinical research, or participation in this study within 3 months prior to admission.\n12. Other conditions that the researchers think make the patient unsuitable for the study.",{"count":100,"type":20},100,[78],"The purpose of this study is to determine the efficacy and safety of plasma adsorption for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.",[104,29],"Acute Ischemic Stroke From Large Vessel Occlusion",[106,107,29],"Acute ischemic stroke","Plasma adsorption","NOT_YET_RECRUITING","2025-06-27",{"date":111,"type":38},"2025-06-29",{"date":113,"type":20},"2025-06-30",{"date":115,"type":20},"2027-06-30",{"name":117,"class":45},"Yi Yang",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":126,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":46},"100559080","a-multicenter-randomized-controlled-clinical-investigation-to-evaluate-the-safety-and-effectiveness-of-the-super-bore-87f-aspiration-catheters-in-the-treatment-of-acute-intracranial-large-vessel-occlusion-100559080","NCT06559475","A Multicenter, Randomized Controlled Clinical Investigation to Evaluate the Safety and Effectiveness of the Super-Bore 8\u002F7F Aspiration Catheters in the Treatment of Acute Intracranial Large Vessel Occlusion","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. Clinical presentation consistent with acute ischemic stroke (AIS);\n3. Able to receive mechanical thrombectomy within 24 hours of onset;\n4. Pre-morbid mRS score of 0 or 1;\n5. Baseline NIHSS score of 6 or greater;\n6. Complete or near-complete occlusion (eTICI 0-1) of the intracranial segment of the internal carotid artery (ICA), the M1 segment of the middle cerebral artery (MCA), or the basilar artery (with or without involvement of the intracranial vertebral artery) confirmed by angiography who can undergo intravascular thrombectomy;\n7. Vessel diameter ≥2.2 mm at the occlusion site;\n8. ASPECTS or PC-ASPECTS score of 6-10 on NCCT, CTA-source imaging, or DWI-MRI;\n9. Written informed consent obtained from the patient or the patient's qualified representative.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Severe allergic reactions to contrast agents;\n3. Current participation in other clinical studies;\n4. Known hereditary or acquired bleeding disorders, platelet count \\\u003C50,000\u002FµL, or coagulation factor deficiencies;\n5. Renal failure with serum creatinine ≥3 mg\u002FdL or Glomerular Filtration Rate (GFR) \\\u003C30 mL\u002Fmin;\n6. Expected survival \\\u003C 6 months or known cancer with metastases;\n7. Clinical manifestations suggesting subarachnoid hemorrhage, despite normal CT or MRI findings;\n8. Suspected aortic dissection;\n9. Known arterial condition in a proximal vessel that requires treatment or prevents access to the site of occlusion or safe recovery of the investigational device (for example, severe stenosis, complete occlusion in the cervical ICA, tandem occlusion);\n10. High degree of suspicion of intracranial arterial disease (ICAD), such as evidence of multifocal ICAD on CTA, MRA, or DSA, or any other finding that is highly suggestive of ICAD as the underlying etiology of the occlusion;\n11. Evidence of dissection in the extracranial or intracranial cerebral arteries;\n12. Intracranial hemorrhage on CT or MRI;\n13. Evidence of intracranial mass effect or tumor (except small meningiomas defined as ≤ 3cm and asymptomatic)) on CT or MRI;\n14. Suspicious of cerebral vasculitis or infectious endocarditis;\n15. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluation, e.g., dementia with prescribed anti-cholinesterase inhibitor;\n16. Clinical history, past imaging or clinical judgement suggest that the intracranial occlusion is chronic;\n17. Excessive vascular access tortuosity or target vessel size that will likely prevent endovascular access with the Super-Bore Aspiration Catheters;\n18. Intracranial stent implanted in the same vascular territory that would preclude the safe deployment\u002Fremoval of the thrombectomy devices;\n19. Occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior circulation\u002Fvertebrobasilar system) as confirmed on CTA\u002FMRA, or clinical evidence of bilateral strokes or strokes in multiple territories as determined by the treating physician;\n20. Known aneurysm at or near the target treatment segment;\n21. Known glucose level\\\u003C 50 mg\u002Fdl (2.78 mmol\u002FL) or \\> 400 mg\u002Fdl (22.20 mmol\u002FL)；\n22. Patients who, in the opinion of the investigator, are unsuitable for mechanical thrombectomy as evidenced by imaging findings.",{"count":125,"type":20},360,[78],"To Evaluate the Safety and Efficacy of the Super-Bore 8\u002F7F Thrombosis Aspiration Catheter in the Treatment of Acute Intracranial Large Vessel Occlusion.",[27,29],[27,130,131],"Super-Bore 8F Thrombosis Aspiration Catheter","Acute Intracranial Large Vessel Occlusion","2024-12-14",{"date":134,"type":38},"2024-12-18",{"date":136,"type":20},"2024-12-16",{"date":138,"type":20},"2026-04-01",{"name":140,"class":45},"The First Affiliated Hospital of University of Science and Technology of China",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100565686","ai-driven-cta-reconstruction-for-intracranial-lvo-100565686","NCT06645405","AI-Driven CTA Reconstruction for Intracranial LVO","Segmentation and Modeling for Accurate Reconstruction of CT Angiography of Intracranial Large Vessel Occlusion with Artificial Intelligence: a Stepped-wedge, Cluster-randomized Controlled Trial","SMART-AI","Inclusion Criteria:\n\n1. Male or Female, 18 years of age or older.\n2. Patients who present with signs and\u002For symptoms concerning acute ischemic stroke.\n3. Patients who undergo noncontrast CT and CT angiography imaging.\n4. Patients determined to have an intracranial large vessel occlusion (including the internal carotid artery, middle cerebral artery M1 segment, and M2 segment), and eligible for endovascular treatment.\n\nExclusion Criteria\n\n1\\) CT imaging with severe motion artifacts.","95 Years",{"count":151,"type":20},174,[78],"Acute ischemic stroke (AIS) caused by intracranial large vessel occlusion (LVO) in the anterior circulation significantly contributes to stroke-related disability and mortality. Recent randomized controlled trials have demonstrated substantial benefits of endovascular thrombectomy (EVT) when patients are appropriately triaged beforehand. However, accurately orienting the 'missed segment' during EVT remains challenging. Guide-wires often fail to navigate through the occlusion or are mistakenly directed into the small tranches or even cause vessel rupture. To address this clinical need, the investigators developed an artificial intelligence (AI) algorithm to automate the reconstruction of CT angiography (CTA), focusing on the occluded LVO segment. To evaluate the clinical utility of this AI algorithm, the investigators propose a prospective, stepped-wedge cluster-randomized study to determine whether integrating our AI algorithm into AIS care flow can reduce the time for first pass of the thrombus by improving the visualization of the occluded segment on CTA. Physicians will assess patient eligibility for thrombectomy, and all selected patients will receive standard care according to current guidelines. This approach is expected to enhance patient treatment outcomes for endovascular thrombectomy by leveraging readily available data.",[27,155,29,156],"Artificial Intelligence (AI)","CT Angiography","2024-10-15",{"date":159,"type":38},"2024-10-16",{"date":161,"type":20},"2024-10-20",{"date":163,"type":20},"2025-12-31",{"name":165,"class":45},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",2,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":46},"100527363","evaluation-of-endovascular-treatment-in-acute-intracranial-distal-medium-vessel-occlusion-stroke-100527363","NCT06146790","Evaluation of Endovascular Treatment in Acute Intracranial Distal Medium Vessel Occlusion Stroke","Evaluation of Endovascular Treatment in Acute Intracranial Distal Medium Vessel Occlusion Stroke - a Multicenter, Randomized Controlled, Clinical Trial","Inclusion Criteria:\n\n1. Age ≥18 years (no upper age limit).\n2. Evidence of a primary (e.g., not secondary to EVT of proximal vessel occlusion) distal medium vascular occlusion defined as occlusion of the co\u002Fnon-dominant M2 segment\\* or M3 segment of the MCA, the ACA (A1, A2, or A3 segments), or the PCA (P1, P2 or P3 segments) resulting in significant clinical deficits and expected to be treatable by endovascular thrombectomy.\n\n   \\* Co\u002Fnon-dominant M2 segment vessel diameter should not exceed 2.0 mm. Co-dominant supplying 50% of the MCA territory vs non-dominant supplying \\\u003C50% of the MCA territory.\n3. Premorbid mRS ≤ 2.\n4. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6 at the time of randomization.\n5. Time from onset (or time last seen well) to randomization\\\u003C24 hours.\n6. For patients with more than 6 hours of onset (or time last seen well), Clinical-Imaging mismatch assessment defined as any of the following scenarios (A or B):\n\n   A. Non-contrast CT of the head or Brain MRI DWI lesion with \\\u003C50% involvement of the vascular territory corresponding to the clinical manifestation:\n\n   B. Target Mismatch Profile on CT perfusion or MRI (Mismatch Volume \\>10cc and mismatch Ratio \\>1.4 ).\n7. Informed consent obtained from patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage on baseline CT\u002FMR (SDH\u002FSAH\u002FICH).\n2. Rapidly improving symptoms, particularly if in the judgment of the managing clinician that the improvement is likely to result in the patient having an NIHSS score of \\\u003C6 at randomization.\n3. Significant ischemic changes in a territory other than the occluded site that in the opinion of the investigator could reduce the benefit of endovascular treatment.\n4. Contra indication to imaging with MR or CT with contrast agents.\n5. Any terminal illness such that patient would not be expected to survive more than 1 year.\n6. Recent past history or clinical presentation of ICH, subarachnoid hemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm other than meningioma.\n7. Any imaging findings suggestive of futile recanalization in the judgment of the local investigator.\n8. seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS.\n9. Baseline blood glucose of \\\u003C50 mg\u002FdL (2.78 mmol) or \\>400 mg\u002FdL (22.20 mmol).\n10. Known history of hereditary or acquired hemorrhagic diathesis and\u002For platelet count \\\u003C50×109\u002FL.\n11. Known renal failure as defined as serum creatinine levels \\> 260umol\u002Fl（3.0 mg\u002FdL）.\n12. Presumed septic embolus or suspicion of bacterial endocarditis.\n13. Any other condition that, in the opinion of the investigator could impose hazards to the patient or affect the participation of the patient in the study if an endovascular procedure was performed.\n14. History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.\n15. Subjects with occlusions in multiple vascular territories (e.g., bilateral or multi-territorial anterior circulation, or anterior\u002Fposterior circulation)\n16. Subject participating in a study involving an investigational drug or device that would impact this study.\n17. Known pregnancy.\n18. Prisoner or incarceration",{"count":175,"type":20},564,[78],"Rationale: Distal Medium Vessel Occlusion (MeVO) are thought to cause as many as 25% to 40% of all acute ischemic strokes (AIS). Despite their relatively high frequency, there is no consensus regarding the optimal management of these patients. However, the fact that AIS related to MeVO often results in significant disability despite best medical treatment (including intravenous thrombolysis, IVT) calls for novel treatment approaches. Fortunately, a growing number of non-randomized studies have now been published demonstrating the feasibility of endovascular treatment (EVT) for MeVO strokes. These studies have demonstrated that distal EVT leads to high rates of successful reperfusion and may be performed with a comparable safety profile to that of EVT for proximal arterial occlusions. Therefore, a strong rational exists to test the safety and efficacy of EVT for MeVO stokes in a prospective randomized clinical trial.\n\nObjectives: The primary objective of this study is to evaluate the hypothesis that endovascular thrombectomy is superior to standard medical management in achieving more favorable outcomes according to the modified Rankin Scale scores at 90 days in subjects presenting with acute ischemic stroke related to a distal medium vessel occlusion within 24 hours from symptom onset (defined as time last know well, TLKW).\n\nSecondary objectives include the assessment of the cost-effectiveness of endovascular thrombectomy in the medium vessel occlusion (MeVO) population as well as its impact on health-related quality of life.\n\nStudy design: The study is a prospective, multicenter, investigational, randomized, controlled, open-label study with blinded endpoint evaluation (PROBE design) and an adaptive design with population enrichment.\n\nStudy population: Subjects presenting with acute ischemic stroke within 24 hours from TLKW and whose strokes are attributable to a distal medium vascular occlusion defined as co\u002Fnon-dominant M2 segment or M3 segment of the MCA, the ACA (A1, A2, or A3 segments), or the PCA (P1, P2 or P3 segments) with evidence of salvageable brain tissue on perfusion imaging, M2 segment vessel diameter should not exceed 2.0 mm.\n\nPrimary outcome: Shift in distribution of all levels of the 90-day the modified Rankin Scale with levels 5-6 combined (mRS; 0, 1, 2, 3, 4, 5-6) as assessed by structured assessment.",[27,29],[180,181,182,183],"Medium Vessel Occlusion","Stroke Due To Medium Vessel Occlusion","Endovascular Treatment","Standard Medical Management","2024-08-31",{"date":186,"type":38},"2024-09-05",{"date":188,"type":38},"2023-12-14",{"date":190,"type":20},"2026-03-01",{"name":140,"class":45},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":46},"100402217","effects-of-post-operative-sedation-for-endovascular-thrombectomy-100402217","NCT04517383","Effects of Post-Operative Sedation for Endovascular Thrombectomy","Effects of Post-operative Sedation on Clinical Outcomes in Patients Receiving Endovascular Thrombectomy for Acute Ischemic Stroke","POSET","Inclusion Criteria:\n\n1. are between 18 and 85 years old\n2. have a clinical diagnosis of AIS due to anterior circulation large artery occlusion (including internal carotid artery or\u002Fand middle cerebral artery)\n3. with a score on the National Institute of Health Stroke Scale (NIHSS) ≥10 before surgery\n4. with a modified Rankin scale (mRS) \\\u003C3 before stroke\n5. have endovascular thrombectomy under GA and are confirmed to achieve successful reperfusion (mTICI 2b-3) by digital subtraction angiography (DSA) exam at the end of the operation.\n6. Informed consent by the patient him-\u002Fherself or his\u002Fher legal representative\n\nExclusion Criteria:\n\n1. previous intracranial hemorrhage within 6 weeks\n2. vascular stents implantation in the responsible blood vessel\n3. Glasgow score ≤8 points before surgery\n4. known allergy to heparin, aspirin, clopidogrel, rapamycin, lactic acid polymer, stainless steel, and allergy or contraindication to contrast agent\n5. contraindication to dexmedetomidine\n6. known hemoglobin less than 70g\u002FL, platelet count less than 50×109L, international normalized ratio (INR) greater than 1.5, or other uncorrectable bleeding issues\n7. severe liver or kidney dysfunction, i.e. ALT or AST \\>3 times the upper limit of normal, or creatinine \\>1.5 times the upper limit of normal\n8. are pregnant or breast feeding\n9. have history of mental illness\n10. are currently participating in another clinical trial.","85 Years",{"count":202,"type":20},1286,[78],"Studies from our lab indicated that long-term sedation is protective in mice with midbrain infarct. To assess whether post-operative sedation has protective effects on clinical outcomes in patients with ischemic stroke undergoing endovascular thrombectomy (ET), a multi-center, randomized clinical trial will be carried out (POSET study). In POSET study, patients receiving ET for acute ischemic stroke under general anesthesia will be randomly assigned to the control group (Con group) and the post-operative sedation group (POS group). Patients in the Con group will be recovered and extubated immediately after the surgery, whereas those in the POS group will be sedated with propofol and dexmedetomidine for another 6hrs before extubation. The primary endpoint is the score on the modified Rankin Scale assessed at 90±7 days after randomization. The hypothesis is that patients in the POS group will have improved clinical outcome in 3 months after surgery.",[27,29],"2024-07-02",{"date":208,"type":38},"2024-07-03",{"date":210,"type":38},"2021-11-24",{"date":212,"type":20},"2025-12-30",{"name":214,"class":45},"RenJi Hospital",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":46},"100495753","patient-selection-using-mr-with-non-perfusion-imaging-for-endovascular-treatment-within-6-to-24-hours-100495753","NCT05735301","Patient Selection Using MR With Non-Perfusion Imaging for Endovascular Treatment Within 6 to 24 Hours","Patient Selection Based on Penumbra-core Mismatch Using MR With Non-Perfusion Imaging for Endovascular Treatment Within 6 to 24 Hours: Rationale and Trial Design","MIELS","Inclusion Criteria:\n\n* Age of 18 years or older；\n* Anterior circulation LVO (internal carotid artery, or middle cerebral arteries (MCA)M1, M2 proximal segment) confirmed by computed tomographic angiography (CTA)\u002Fmagnetic resonance angiography (MRA)；\n* NIHSS score ≥6 at the time of randomization；\n* ASPECTS score ≥ 6 on NCCT；\n* Time from stroke onset to randomization within 6-24 hours；\n* Pre-stroke mRS score 0-2；\n* Completed MRI and perfusion imaging or enable to complete MRI and\u002For perfusion imaging；\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnancy, or those potential with positive urine or serum beta Human Chorionic Gonadotrop in test；\n* A history of severe allergy to contrast media；\n* Uncontrolled hypertension (SBP \\>185mmHg; DBP\\>110mmHg)；\n* Hereditary or acquired bleeding tendency, coagulation factor deficiency, recent anticoagulant medication (A platelet count of less than 100 x 109 \u002FL；INR\\>3 or PPT more than 3 times normal)；\n* Active hemorrhage or preexisting tendency to hemorrhage；\n* Presence of signs of cardiac, hepatic or renal failure；\n* Baseline blood glucose\\\u003C50mg\u002FdL (2.78mmol) or \\>400mg\u002FdL (22.20mmol)；\n* Participation in other interventional randomized clinical trials that may confound the outcome assessment of the trial；\n* Life expectancy \\\u003C 1 year；\n* Patients who are unable to complete the 90-day follow-up；\n* A stroke attack with epilepsy that prevents an accurate NIHSS score from being obtained；\n* Other circumstances that the investigator considers inappropriate for participation in the trial(such as violation of guidelines or institutional processing principles during the screening process).",{"count":224,"type":20},352,[78],"We will conduct a multicenter, prospective, randomized, open-label, blinded endpoint trial with a non-inferiority design in patients who present 6 to 24 hours after symptom onset with LVO. Patients who meet eligibility criteria will be randomly assigned to the Non-perfusion or Perfusion group with a 1:1 ratio. In the Non-perfusion group, patients with penumbra-core mismatch (defined as the FLAIR Vascular Hyperintensity (FVH) extending beyond the boundary of the DWI cortical lesions) will receive EVT. In the Perfusion group, patients with perfusion mismatch (defined as regional cerebral blood flow (\\\u003C30%) \\\u003C 70 ml with mismatch ratio ≥ 1.8 and mismatch volume ≥ 15 ml) will receive EVT. Patients in both groups will receive guideline-based medical treatment. If patients in both groups do not meet the criteria for EVT, only guideline-based medical treatment will be administered.",[29],[229,230,231,232,233],"select patients","endovascular thrombectomy","magnetic resonance imaging","CT\u002FMR perfusion","FVH-DWI mismatch","2024-06-20",{"date":236,"type":38},"2024-06-24",{"date":238,"type":38},"2019-01-01",{"date":240,"type":20},"2024-09",{"name":242,"class":45},"Tianjin Huanhu Hospital",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":253,"phases":4,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":46},"100531511","triage-of-patients-presenting-beyond-24-hours-with-acute-ischemic-stroke-due-to-large-vessel-occlusions-track-lvo-late-100531511","NCT06200753","Triage of Patients Presenting Beyond 24 Hours With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO Late)","Triage of Patients Presenting Beyond 24 Hours From Last Known Well With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO Late): a TRACK-LVO Registry-linked Cohort","TRACK-LVO Late","Inclusion Criteria:\n\n* Patient admitted from Jan. 1st 2018 to Jan. 1st 2028;\n* Presenting beyond 24 hours from last known well;\n* Ischemic stroke confirmed by head CT or MRI;\n* Large vessel occlusion confirmed by head CTA or MRA: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1\u002FM2), anterior cerebral artery (ACA A1\u002FA2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1\u002FP2);\n* Patients receiving either endovascular therapy or best medical treatment.\n\nExclusion Criteria:\n\n• Presence of any forms of cerebral hemorrhage on CT\u002FMR at admission.",{"count":252,"type":20},1000,"OBSERVATIONAL","The objective of this study is to create a comprehensive, multi-center, TRACK-LVO registry-linked cohort of consecutive patients with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO) and presenting to each participating center beyond 24 hours from last known well, who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).",[29,256,27],"Large Vessel Occlusion",[258],"Acute Ischemic Stroke, Endovascular Therapy,","2023-12-30",{"date":261,"type":38},"2024-01-11",{"date":263,"type":38},"2018-01-01",{"date":265,"type":20},"2028-12-31",{"name":242,"class":45},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":253,"phases":4,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":288},"100523352","medical-imaging-screening-for-posterior-circulation-ischemic-stroke-100523352","NCT06094569","Medical Imaging Screening for Posterior-circulation Ischemic Stroke","Medical Imaging Screening for Posterior-circulation Ischemic Stroke：a Multicentre,Imaging-based,Prospective Cohort Study","Inclusion Criteria:\n\n1. Patient admitted from Jun. 1st 2019 to Jan. 1st 2029;\n2. Patients with acute ischemic stroke recently；\n3. Symptoms persisted at admission, and MRI (including DWI) confirmed acute ischemic vertebrobasilar artery occlusion in the posterior circulation:（single right or left intracranial branch of vertebral artery occlusion ; single basilar occlusion ; both two vertebral arterys and basilar artery）；\n\nExclusion Criteria:\n\n1.Patiens can not meet the MRI examination conditions(with absolute and relative contraindications).",{"count":252,"type":20},"Patients with ischemic stroke in the posterior circulation continue to have high rates of mortality and disability, even with aggressive treatment. We wanted to evaluate preoperative imaging to screen patients with a good prognosis from mechanical embolization. We assess the degree of ischemia by defining the pons-midbrain-medulla index (PMMI) and correlate the preoperative PMMI with the clinical prognosis of postoperative patients to verify the validity of PMMI in predicting the clinical prognosis of patients with embolization.",[29],[229,230,231,278,279],"diffusion weighted imaging","Vertebrobasilar artery","2023-10-16",{"date":282,"type":38},"2023-10-23",{"date":284,"type":38},"2019-06-01",{"date":286,"type":20},"2029-12-31",{"name":242,"class":45},4]